The Cooper Companies/$COO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About The Cooper Companies

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.

Ticker

$COO
Sector
Primary listing

Employees

16,000

COO Metrics

BasicAdvanced
$13B
32.69
$2.04
1.00
-

What the Analysts think about COO

Analyst ratings (Buy, Hold, Sell) for The Cooper Companies stock.

Bulls say / Bears say

In Q3 FY2025, CooperCompanies reported revenue of $1.0603 billion, up 6% year-on-year, and non-GAAP diluted EPS of $1.10—a 15% increase that topped the $1.07 consensus—enabling management to raise full-year EPS guidance to $4.08–$4.12 (Reuters).
CooperVision’s Q3 revenue grew 6%, driven by strong performance in Toric and multifocal lenses, reinforcing the company’s leadership in premium contact lens segments (Reuters).
The company repurchased $52.1 million of common stock in Q3 under its buyback program—with $163.6 million of capacity remaining—demonstrating robust cash generation and commitment to shareholder returns (Reuters).
CooperSurgical’s product line exit in Q3 adversely impacted GAAP gross and operating margins, highlighting restructuring costs that weighed on profitability (Reuters).
Despite a 6.3% year-on-year revenue increase to $1.00 billion in Q2—inline with the $995.35 million consensus—CooperCompanies’ shares fell 5% during the quarter and were down 12.8% year-to-date, signaling investor skepticism over growth sustainability (Reuters).
GAAP diluted EPS of $0.44 in Q2 represented less than half of the $0.96 non-GAAP EPS, underscoring substantial adjustments and non-recurring charges that may obscure the company’s underlying earnings power (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.

COO Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

COO Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $COO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs